Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Pet Pharm Biotech CoROCO:7762 +0.20%19 PB Ratio is 2.47 as of Jul. 21, 2026, which is 36% below its 10-year median of 3.86. GuruFocus rates ROCO:7762 with a GF Score™ of 19/100. The stock has 5 warning signs investors should review. Among 921 Drug Manufacturers companies, Pet Pharm Biotech Co ranks worse than 61.02% on this metric.
Pet Pharm Biotech Co Ltd stock PB Ratio (=2.46) is close to 2-year low of 2.32.
The historical rank and industry rank for Pet Pharm Biotech Co's PB Ratio or its related term are showing as below:
ROCO:7762'
s PB Ratio Range Over the Past 10 Years
Min: 2.32 Med: 3.86 Max: 6.25
Current: 2.46
During the past 4 years, Pet Pharm Biotech Co's highest PB Ratio was 6.25. The lowest was 2.32. And the median was 3.86.
ROCO:7762's PB Ratio is ranked worse than 61.02% of 921
companies
in the Drug Manufacturers industry
Industry Median: 1.86
vs ROCO:7762: 2.46
During the past 12 months, Pet Pharm Biotech Co's average Book Value Per Share Growth Rate was 48.50% per year.
During the past 3 years, the average Book Value Per Share Growth Rate was 86.00% per year.
During the past 4 years, the highest 3-Year average Book Value Per Share Growth Rate of Pet Pharm Biotech Co was 86.00% per year. The lowest was 86.00% per year. And the median was 86.00% per year.
Back to Basics: PB Ratio
Pet Pharm Biotech Co (ROCO:7762) PB Ratio Explanation
The PB Ratio works the best for the businesses that earn most of their profit from their assets, e.g. banks and insurance companies.
Be Aware
Some businesses have very light assets, such as software companies or insurance agencies. The PB Ratio does not work well for these companies. Some companies even have negative equity, so the PB Ratio cannot be applied to them.
Pet Pharm Biotech Co PB Ratio Related Terms
Pet Pharm Biotech Co PB Ratio Historical Data
* Premium members only.
The historical data trend for Pet Pharm Biotech Co's PB Ratio can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Drug Manufacturers - General subindustry, Pet Pharm Biotech Co's PB Ratio, along with its competitors' market caps and PB Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Pet Pharm Biotech Co PB Ratio vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Pet Pharm Biotech Co's PB Ratio distribution charts can be found below:
* The bar in red indicates where Pet Pharm Biotech Co's PB Ratio falls into.
The PB Ratio, or Price-to-Book ratio, or Price/Book, is a financial ratio used to compare a company's market price to its Book Value per Share. It is a ratio widely used to value stocks.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
It can also be calculated from the numbers for the whole company:
A closely related ratio is called Price-to-Tangible-Book. The difference between Price-to-Tangible-Book and PB Ratio is that book value other than intangibles are used in the calculation.
Pet Pharm Biotech Co (ROCO:7762) has a PB Ratio of 2.47 as of Jul. 21, 2026. Price-to-Book ratio is the ratio of share price to a company's book value per share. View historical data on Pet Pharm Biotech Co and its competitors. This is 36% below median its historical median of 3.86. Over the past decade, Pet Pharm Biotech Co's PB Ratio has ranged from 2.32 to 6.25. According to the industry distribution chart, Pet Pharm Biotech Co ranks #562 out of 921 companies in the Drug Manufacturers industry, placing it in the top 61%.
Is Pet Pharm Biotech Co's PB Ratio too high?
Pet Pharm Biotech Co's current PB Ratio of 2.47 is 36% below median its 10-year median of 3.86. Over the past 10 years, this metric has ranged from a low of 2.32 to a high of 6.25. The Drug Manufacturers industry median PB Ratio is 1.86. Pet Pharm Biotech Co's value of 2.47 is 32.8% above this industry median. Based on the distribution chart, Pet Pharm Biotech Co ranks #562 out of 921 companies in the Drug Manufacturers industry, which is below the industry midpoint. Overall, Pet Pharm Biotech Co has a GF Score™ of 19/100, reflecting its overall financial health beyond just this single metric.
How does Pet Pharm Biotech Co's PB Ratio compare to LLY and JNJ?
According to the Drug Manufacturers industry distribution chart, Pet Pharm Biotech Co ranks #562 out of 921 companies for PB Ratio. This places Pet Pharm Biotech Co in the lower half of its industry. The industry median PB Ratio is 1.86. Pet Pharm Biotech Co's value of 2.47 is 32.8% above this benchmark. Historically, Pet Pharm Biotech Co's own PB Ratio has ranged from 2.32 to 6.25 over the past decade. While the company's 10-year median is 3.86 vs. the industry median of 1.86, Pet Pharm Biotech Co has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good PB Ratio for a Drug Manufacturers company?
The median PB Ratio among Drug Manufacturers companies is 1.86, based on 921 companies in the industry. Companies in the top quartile (top 25%) have a PB Ratio significantly above this median, while those in the bottom quartile fall well below. However, PB Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Pet Pharm Biotech Co's current PB Ratio of 2.47 is 32.8% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high PB Ratio mean?
A high PB Ratio can signal that a stock is expensive relative to its fundamentals. Price-to-Book ratio is the ratio of share price to a company's book value per share. View historical data on Pet Pharm Biotech Co and its competitors. For the Drug Manufacturers industry, the median PB Ratio is 1.86 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Pet Pharm Biotech Co's current PB Ratio is 2.47, which is 36% below median its own 10-year median of 3.86. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Pet Pharm Biotech Co stock overvalued right now?
Pet Pharm Biotech Co (ROCO:7762) has a current PB Ratio of 2.47. The current PB Ratio is 2.47, which is 36% below median its 10-year median of 3.86 and 32.8% above the Drug Manufacturers industry median of 1.86. Pet Pharm Biotech Co's overall GF Score™ is 19/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is PB Ratio calculated?
PB Ratio is calculated from a company's financial statements. For Pet Pharm Biotech Co (ROCO:7762), the current PB Ratio is 2.47 as of Jul. 21, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Pet Pharm Biotech Co Ltd is a Pharmaceutical company. The company is engaged in manufacturing medicinal products and medicine drugs. The products offered by the company include FDG Fluodeoxyglucose Injection (18F-FDG), Naolixi Injection (18F-FBB), Sodium fluoride injection (18F-NaF), and others.
19GF Score
Get the complete analysis for ROCO:7762
PB Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
ROCO:7762 has been successfully added to your 
